Agenus Inc. · NASDAQ:AGEN
Agenus — Deutsche Bank's 43rd Annual Health Care Conference (May 2018)
26 slides from Agenus's conference presentation, May 8, 2018
Slide 1: Agenus – May 8, 2018
AgeCNUS _ (in) (¥)
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q fil
Slide 3: Agenus – Innovation and Speed
Process Today Agenus – Innovation chart with three phases and Speed I-O Capabilities Speed & Optimal & Portfolio Efficiency Combinations 4 Therapeutic modalities CPMs, Vaccines, Cell 5 INDs^ Filed in 2016 – 2017 I-O backbone CTLA-4 and PD-1 Therapy*, Adjuvants INDs^ Technology platforms 6 On track f
Slide 4: Key Acquisitions
Key Acquisitions Discovery and development of checkpoint antibodies QS-21 Stimulon® • >12 programs • Most powerful adjuvant • Cell line development • Adjuvant in most effective Shingles • GMP manufacturing vaccine (SHINGRIX) Integrated GMP Antibody Manufacturing • Rapid discovery to clinical materia
Slide 5: Portfolio Designed for Rapid BLA, Effective Combinations & Opportunistic Market Expansion
Portfolio Designed for Rapid BLA, Effective Combinations & Opportunistic Market Expansion 5
Slide 6: Delivering on Our Partnerships
Delivering on Our Partnerships Shingrix with Agenus Multiple combination 1 undisclosed target QS-21 Stimulon® Ph2s ongoing: • Lead selection completed • Most effective Shingles • INCAGN1876 (GITR) vaccines (up to 97% • INCAGN1949 (OX-40) • Initial milestone received; efficacy) • Dose escalation comp
Slide 7: Jennifer Buell, PhD
Jennifer Buell, PhD Chief External Affairs and Communications Officer ▪ Foundational checkpoint antibodies ▪ Novel discoveries ▪ Neoantigen vaccines ▪ AgenTus, cell therapy subsidiary
Slide 8: Foundational Checkpoint Antibodies
Foundational Checkpoint Antibodies Critical enablers of I-O combination therapy
Slide 9: PD-1 and CTLA-4 Required as Backbone of Innovative Combos
PD-1 and CTLA-4 Required as Backbone of Innovative Combos PD-1 / CTLA-4 is only validated I-O/I-O antibody combination NEXT-GENERATION CTLA-4 +/- PD1 Therapies (cell therapy, mAbs, AGEN20341: VALIDATED Targets bispecifics, ADCs, Anti-PD-1 mAb – targeted therapies, Phase 2 ongoing vaccines, etc.) AGE
Slide 10: Where PD-1 works, CTLA-4 Improves Responses and Durability
Where PD-1 works, CTLA-4 Improves Responses and Durability Objective Trial Name Indication Treatment(s) Response Rate (ORR) CheckMate 037 Melanoma Nivolumab 32% CheckMate 069 Melanoma Nivo + Ipi 61% KEYNOTE 016 MSI-H CRC Pembrolizumab 40% CheckMate 142 MSI-H CRC Nivo + Ipi 81% Presented by Steven Le
Slide 11: AGEN1884 (CTLA-4) and AGEN2034 (PD-1) – Clinically Active
AGEN1884 (CTLA-4) and AGEN2034 (PD-1) – Clinically Active • >100 patients treated; clinical responses observed • Pharmacology/pharmacodynamic characterization Patient with advanced cancer; complete CTLA-4 (AGEN1884) Dose Frequency responder post AGEN1884 treatment AGEN1884 0.1, 0.3, 1, 3, 6 mg/kg Q3
Slide 12: Planned Path to BLA: AGEN2034 (PD-1) & AGEN1884 (CTLA-4)
Planned Path to BLA: AGEN2034 (PD-1) & AGEN1884 (CTLA-4) 2017 2018 2019 2020 Q1 Q2 Q3 Q4 Q4 Q1 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 AGEN1884 Ph 1 AGEN2034 P1/2 Trials designed as registrational trials to support a rapid BLA filing AGEN1884 plus AGEN2034 2L Cervical cancer* AGEN1884 and AGEN2034 undis
Slide 13: Novel Immunomodulatory Antibodies & Bispecifics
Novel Immunomodulatory Antibodies & Bispecifics Enabling cancer immune modulation beyond the T cell
Slide 14: An Integrated Approach to Target Discovery in Immuno-Oncology
An Integrated Approach to Target Discovery in Immuno-Oncology Physiological Perturbation assays libraries Novel Targets Biomarkers Combinations reinvigorating the immune system Readout / analysis In vivo material platforms and data 14
Slide 15: High Throughput Discoveries; New Clinical Programs in ~2yrs
High Throughput Discoveries; 6 New Clinical Programs in ~2yrs* HIT HIT LEAD CELL LINE ASSET DISCOVERY OPTIMIZATION OPTIMIZATION DEVELOPMENT Undisclosed bispecific #1 First-in-class Opportunity Treg depletion, agonist costimulation Undisclosed bispecific #2 First-in-class Opportunity TME conditioning
Slide 16: Next-Generation CTLA-4 with Novel Mechanisms – Planned IND 2018
Next-Generation CTLA-4 with Novel Mechanisms – Planned IND 2018 Mechanism #1 Mechanism #2 Mechanism #3 Blockade of CD80 & CD86 Depletion of intratumoral Tregs Agenus discovery binding to CTLA-4 via co-engagement of FcγRs Enhanced T cell priming Primary T cell Assay 15000 Ligand blocking assay IL -2
Slide 17: Best in Class & First in Class Bispecifics – Planned for IND in 2018
Best in Class & First in Class Bispecifics – Planned for IND in 2018 • Regulatory T cells impair productive anti-tumor immune responses with multiple mechanisms of suppression • Targeted elimination of regulatory T cells within the TME would address multiple suppressive mechanisms (i.e. in a single
Slide 18: Neoantigen Vaccine Platform
Neoantigen Vaccine Platform Enabling differentiated personalized and warehouse vaccine offerings
Slide 19: ASV™ Clinically Validated Neoantigen Vaccine Platform
ASV™ Clinically Validated* Neoantigen Vaccine Platform ASVTM Clinical Status • Clinical safety & immunogenicity with ASVTM • Potential best-in-class vaccine blueprint neoantigen vaccine platform demonstrated* with QS-21 Stimulon® adjuvant for efficacy • Combo with CPMs planned for 2018 and manufactu
Slide 20: AgenTus Therapeutics
www.agentustherapeutics.com www.agenusbio.com
Slide 21: Agenus and AgenTus Designed to Expand Response Rates and Durability
Agenus and AgenTus Designed to Expand Response Rates and Durability Innovation & Speed Next generation agents Cancer Cures + 21
Slide 22: Differentiated Cancer Cell Therapy
Differentiated Cancer Cell Therapy Precision T-Rx Mammalian Display - Direct selection for function Receptors Targets optimal balance between activity and specificity Novel Proprietary target discovery and validation platforms Targets Proprietary Phosphopeptide Tumor Targets Allogeneic Allogeneic ap
Slide 23: Superior Receptor Discovery Through T-Rx Platform
Superior Receptor Discovery Through T-RxTM Platform A powerful engine for delivering efficient and specific TCRs Agenus Mammalian Display: Retrocyte DisplayTM and T-RxTM Agenus mammalian display platform has delivered clinical antibodies currently in Ph1/2 clinical programs* Retroviral transduction
Slide 24: Agenus is Industry Leader in Discovery of Novel Phosphopeptide Tumor Targets
Agenus is Industry Leader in Discovery of Novel Proprietary Phosphopeptide Tumor Targets (PTTs) Cancer Neo-Antigens Nature of Mutations Deregulated Expression Deregulated Signaling change Consequence Mutation Over-expression Ectopic Expression Post-Translational Modifications for Proteins (phosphory
Slide 25: AgenTus Emerged from Agenus – A Differentiated Cell Therapy Company
AgenTus Emerged from Agenus – A Differentiated Cell Therapy Company Checkpoint antibodies Synergies Antibodies Adoptive Cell Therapy Improve response Direct attack Combinations Cancer vaccines Improve recognition Adjuvants Boost recognition 25
Slide 26: www.agentustherapeutics.com www.agenusbio.com www.agentustherapeutics.com
www.agentustherapeutics.com www.agenusbio.com www.agentustherapeutics.com
Agenus — Deutsche Bank's 43rd Annual Health Care Conference (May 2018) on 6ix